Johns Hopkins Medicine, 601 N Caroline St, Baltimore, MD 21287.
AJR Am J Roentgenol. 2022 Jun;218(6):997-998. doi: 10.2214/AJR.21.27162. Epub 2021 Dec 22.
This study describes 94 patients who presented with suspected COVID-19 vaccine-related axillary adenopathy on breast imaging. All biopsies recommended within 12 weeks of the second vaccine dose were benign. Among women not recommended for biopsy, the median interval between the second vaccine dose and ultrasound follow-up was 15.9 weeks. Three biopsies yielding malignant diagnoses were recommended 12.0-13.1 weeks after the second vaccine dose. Lengthening imaging follow-up to 12-16 weeks after the second dose may reduce unnecessary biopsy recommendations.
本研究描述了 94 例在乳腺影像学检查中出现疑似与 COVID-19 疫苗相关的腋窝淋巴结病的患者。所有在第二剂疫苗接种后 12 周内建议进行的活检均为良性。在不建议进行活检的女性中，第二剂疫苗和超声随访之间的中位数间隔为 15.9 周。三例活检建议在第二剂疫苗后 12.0-13.1 周进行，结果为恶性诊断。将影像学随访延长至第二剂疫苗后 12-16 周可能会减少不必要的活检建议。
